Loading...

383 posters, 2 videos, 1 audios, 8 topics, 28 sessions, 328 authors, 225 institutions

ePostersLive by SciGen Technologies S.A. All rights reserved.

6896

LOCAL ANESTHESIA RESISTANCE: IS THERE A ROLE FOR LIPOSOMAL BUPIVACAINE?

Part of Topic

Medically Challenging Cases

Local Anesthetic Resistance: Is there a role for liposomal bupivacaine

 

Background

Insufficient analgesia from local anesthetics (LA) is often attributed to poor technique, tissue inflammation or patient expectations (1). True resistance to LA is not often considered but there is growing literature to support it (1, 2). The underlying mechanism of true LA resistance is unknown, however certain patient populations may be higher risk including those with Ehler-Danlos syndrome (EDS) (3) and red-heads (2), and chronic opioid users (2). We present a who have reported history of true LA resistance and their experience with Liposomal Bupivacaine.

 

Case

60-year-old female with history of Type III (hypermobile) EDS, chronic opioid use presented for revision total shoulder arthroplasty. Patient reported experiencing resistance to LA in the past. A dry Interscalene (IS) catheter was placed pre-op and was bolused post-op with 10 ml of Ropivacaine 0.5%. VAS score dropped from 10 to 8/10 only and physical exam showed intact pinprick and temperature sensation. Ultrasound visualization of an additional bolus of lidocaine showed proper catheter placement. The next day, she mentioned that “peripheral nerve blocks don’t work for me” the only time she had good relief from a nerve block was when liposomal bupivacaine was used for prior shoulder surgery. 6 months later the patient was admitted for another shoulder surgery. An IS with liposomal bupivacaine achieved  adequate analgesia with VAS scores of 2/10 with good patient satisfaction. However, the block lasted only for 16 hours.

 

Discussion

-Genetic analysis of a family identified mutations in the sodium channel which binds local anesthetic in family members with documented LA resistance (6). Clendenen et al, used immunohistochemistry to specify that these mutant receptors are expressed in peripheral nerves (6).
-Ehlers Danlos syndrome patients show variable and inconsistent level of resistance reported in the literature and seen in clinical practice, making it difficult to point to genetic mutation as the only explanation (1, 2).
-Studies have suggested that changes in EDS patients, the microvascular structure, which vary from one anatomical location to another, may influence the rate of LA uptake by the blood (1, 2, 8).
-In a case series looking at EDS patients receiving peripheral nerve blocks with plain LA, all those patients with uncontrolled pain had type III hypermobile EDS (7).
-Our patient had greatly improved pain scores with liposomal bupivacaine but did require opioids and other adjunctive analgesics 12 to 16 hours after the Exparel diminished.
-Exparel appears to have improved analgesia for patients with Ehlers Danlos syndrome albeit with a shorter duration of action compared to other patients.
 
 
Conclusion

Although the mechanism of action is not clearly understood, our case demonstrated a potential benefit of utilizing liposomal bupivacaine for peripheral nerve blocks in patients with Type III EDS who exhibit history of LA resistance. More studies are needed.

asraspring2025 banner
Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.